Evidence map›Paper›PMID 41626475›Full record

ArticleACS omega2026

TropMol-Caipora: A Cloud-Based Web Tool to Predict Cruzain Inhibitors by Machine Learning.

Thiago H Doring

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thiago H DoringDepartment of Exact Sciences and Education (CEE), School of Technology, Exact Sciences and Education (CTE), Federal University of Santa Catarina (UFSC), Blumenau 89036-256, SC, Brazil.ORCID https://orcid.org/0000-0002-3611-9105

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease (CD) affects approximately 8 million people and is classified as a high-priority neglected tropical disease by the WHO research and development actions. One promising avenue for drug development for CD is the inhibition of cruzain, a crucial cysteine protease of

Identifiers

PMID41626475
PMCPMC12854596

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.